Alex Aravanis's experience at Sapphire, making crude oil from algae, reveals a key insight for bio-industrial ventures. The technology worked, but the business model was unviable because it couldn't compete with the volatile, and often low, price of fossil fuels. Success required consistently high oil prices ($200-$300/barrel), which is unsustainable.
Moonwalk didn't start with the goal of treating obesity. The company was founded on a novel drug discovery platform using genomics and genome perturbation technologies. They then applied this platform to various areas and found adipose tissue to be a particularly fruitful area, leading them to their current focus.
Instead of in-licensing a clinical-stage asset, Moonwalk identified its own novel drug targets and then licensed a specific, enabling delivery technology from a Chinese firm. This strategic move allowed them to pair their proprietary targets with best-in-class delivery, focusing on the quality of the science over geopolitical norms.
In the crowded obesity market dominated by GLP-1s, Moonwalk's strategy is to address unmet needs rather than competing on top-line weight loss. By focusing on a non-appetite-suppressing mechanism, they aim to preserve lean muscle mass, reduce side effects, and offer infrequent dosing, creating a compelling therapy for non-responders or as a combination agent.
A key differentiator for Moonwalk's long-acting siRNA therapy is its potential for highly infrequent dosing—quarterly or even semi-annually. This contrasts sharply with the daily pills or weekly injections for current obesity treatments. For a chronic condition, this dramatic improvement in convenience and adherence is a powerful competitive advantage.
Moonwalk's fundraising strategy uses its $70M Series B to achieve clinical proof-of-principle for at least two, and possibly three, different programs. This "multiple shots on goal" approach significantly de-risks the company by creating a pipeline rather than betting everything on a single lead asset, generating more value for the next financing round.
Alex Aravanis advocates a "natural owner" philosophy for commercialization. While Moonwalk is the natural owner for early development, a larger organization with global clinical and commercial infrastructure may become the natural owner for late-stage trials and market launch. This pragmatic approach prioritizes what is best for the asset over building an unnecessary commercial footprint.
Beyond identifying potential drug targets, Moonwalk uses AI to analyze why some targets succeed in animal models while others fail. By feeding its proprietary biological data into large models, the team gains insights into pathways and mechanisms. This deeper understanding helps prioritize candidates and allows the AI to suggest novel, related targets.